Silicon Valley faces a new breed of startup monster: zombie unicorns. These companies once commanded billion-dollar valuations but now struggle to justify their mythical worth. Of 1,900 unicorns tracked by Stanford's Ilya Strebulaev, 332 raised funds at or below peak valuations by May 2026, with 212 falling below the $1bn threshold.

The carnage reflects a harsh reality check. Venture capital fundraising plummeted from $223bn in 2022 to just $66bn last year as interest rates rose. Companies like Cameo, valued at $1bn in 2021, now fetch merely $82m. Many unicorns launched during the easy-money era with thin revenue streams and questionable business models. Pitchbook projects $500bn to $1trn in valuation cuts as firms either restructure, sell, or fold.

For venture capitalists, this spells trouble. Funds launched recently return far less than earlier vintages and badly trail the S&P 500, except for AI-focused investments. Just 5% of VC firms generate 90% of industry profits, concentrating risk among top-tier managers. This imbalance makes fundraising harder for everyone else.

Some VCs pivot to continuous funds mixing private and public stakes, while others explore secondary markets. However, these solutions favor healthy companies, not the walking dead. Even if AI IPOs succeed, resurrecting zombie unicorns requires more than market optimism—it demands viable businesses.